Lindsay A. Horton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lindsay A. Horton has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Lauren Tardo
Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O’Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA
4 shared publications - Benjamin M. Greenberg
Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA
3 shared publications - Morgan McCreary
Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O’Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA
3 shared publications - Peter V. Sguigna
Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O’Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA
3 shared publications - Kyle M. Blackburn
Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, United States
2 shared publications - Anthony T. Reder
University of Chicago Medicine, Chicago, Illinois, USA
1 shared publication
Latest Publications
- Open Access
- 3 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (2) , 192-201
Clinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod
Background: Gilenya ® (fingolimod), a sphingosine-1-receptor agonist, is an effective treatment for multiple sclerosis (MS). However, increased relapse activity has been observed after transitioning to generic fingolimod despite prior prolonged disease stability. Objective: To quantify the clinical and radiological impact of transitioning from Gilenya ® to generic fingolimod in people with MS (PwMS). Methods: Retrospective data were evaluated from a single tertiary MS care center. Time to magnetic resonance imaging (MRI) activity and clinical relapse was assessed during Gilenya ® and generic fingolimod treatment. Differences in absolute lymphocyte count (ALC) and side effects were also measured by treatment group. Results: The cohort included 88 PwMS (71 female; 76 White, mean age when starting Gilenya ® was 39.6 years (standard deviation (SD) = 10.6 years), and mean age when starting generic fingolimod was 46.9 years (SD = 11.2 years)). A shorter time to MRI activity ( p = 0.0026) and time to relapse ( p = 0.0027) was observed during generic fingolimod treatment. The ALC increased by 8.81% after generic fingolimod treatment, relative to Gilenya ® (95% CI = (2.00%, 16.08%), p = 0.01), with an intersubject variability of 1.97%. A 2.45-fold increase in side effects was observed with generic fingolimod relative to Gilenya ® (95% CI = (1.38, 4.36), p = 0.002). Conclusion: Measures of disease stability appear less optimal with generic fingolimod based on serological, clinical, and radiological measures.
- 3 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (2) , 192-201
Open AccessClinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod
Background: Gilenya ® (fingolimod), a sphingosine-1-receptor agonist, is an effective treatment for multiple sclerosis (MS). However, increased relapse activity has been observed after transitioning to generic fingolimod despite prior prolonged disease stability. Objective: To quantify the clinical and radiological impact of transitioning from Gilenya ® to generic fingolimod in people with MS (PwMS). Methods: Retrospective data were evaluated from a single tertiary MS care center. Time to magnetic resonance imaging (MRI) activity and clinical relapse was assessed during Gilenya ® and generic fingolimod treatment. Differences in absolute lymphocyte count (ALC) and side effects were also measured by treatment group. Results: The cohort included 88 PwMS (71 female; 76 White, mean age when starting Gilenya ® was 39.6 years (standard deviation (SD) = 10.6 years), and mean age when starting generic fingolimod was 46.9 years (SD = 11.2 years)). A shorter time to MRI activity ( p = 0.0026) and time to relapse ( p = 0.0027) was observed during generic fingolimod treatment. The ALC increased by 8.81% after generic fingolimod treatment, relative to Gilenya ® (95% CI = (2.00%, 16.08%), p = 0.01), with an intersubject variability of 1.97%. A 2.45-fold increase in side effects was observed with generic fingolimod relative to Gilenya ® (95% CI = (1.38, 4.36), p = 0.002). Conclusion: Measures of disease stability appear less optimal with generic fingolimod based on serological, clinical, and radiological measures.
- Open Access
- 5 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1172993
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients
People identified with Black/African American or Hispanic/Latinx ethnicity are more likely to exhibit a more severe multiple sclerosis disease course relative to those who identify as White. While social determinants of health account for some of this discordant severity, investigation into contributing immunobiology remains sparse. The limited immunologic data stands in stark contrast to the volume of clinical studies describing ethnicity-associated discordant presentation, and to advancement made in our understanding of MS immunopathogenesis over the past several decades. In this perspective, we posit that humoral immune responses offer a promising avenue to better understand underpinnings of discordant MS severity among Black/African American, and Hispanic/Latinx-identifying patients.
- 5 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1172993
Open AccessUnderstanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients
People identified with Black/African American or Hispanic/Latinx ethnicity are more likely to exhibit a more severe multiple sclerosis disease course relative to those who identify as White. While social determinants of health account for some of this discordant severity, investigation into contributing immunobiology remains sparse. The limited immunologic data stands in stark contrast to the volume of clinical studies describing ethnicity-associated discordant presentation, and to advancement made in our understanding of MS immunopathogenesis over the past several decades. In this perspective, we posit that humoral immune responses offer a promising avenue to better understand underpinnings of discordant MS severity among Black/African American, and Hispanic/Latinx-identifying patients.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 9 (1)
Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study
Background: Excessive daytime sleepiness (EDS) in multiple sclerosis (MS) can be a significant source of disability. Despite this, its prevalence as a patient-reported outcome in this condition has not been well established, and its causes are not well understood. Methods: We prospectively assessed EDS as part of an observational study for patients referred for diagnostic neuro-ophthalmological testing. EDS was evaluated by the Epworth Sleepiness Scale (ESS), and visual data were also collected as part of a research protocol. Analysis with patient data was performed following the exclusion of patients with known primary sleep disorders. Results: A total of 69 patients with MS were included in the analysis. The mean ESS was 6.5 with a SD of 4.3. ESS ≥ 10 was present in 23% of the cohort even in the presence of minimal mean neurological disability (Patient Determined Disease Steps (PDDS) = 1.5). The ESS score was not associated with age, sex, disease-related disability, retinal nerve fiber layer (RNFL), or optic neuritis (ON), but displayed an association with visual dysfunction. Conclusions: There is an increased prevalence of EDS in MS. The increased values of the ESS are not explained by other sleep disorders, suggesting separate mechanisms. Further study of the underlying mechanisms is warranted.
- 1 January 2023
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 9 (1)
Open AccessDisease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study
Background: Excessive daytime sleepiness (EDS) in multiple sclerosis (MS) can be a significant source of disability. Despite this, its prevalence as a patient-reported outcome in this condition has not been well established, and its causes are not well understood. Methods: We prospectively assessed EDS as part of an observational study for patients referred for diagnostic neuro-ophthalmological testing. EDS was evaluated by the Epworth Sleepiness Scale (ESS), and visual data were also collected as part of a research protocol. Analysis with patient data was performed following the exclusion of patients with known primary sleep disorders. Results: A total of 69 patients with MS were included in the analysis. The mean ESS was 6.5 with a SD of 4.3. ESS ≥ 10 was present in 23% of the cohort even in the presence of minimal mean neurological disability (Patient Determined Disease Steps (PDDS) = 1.5). The ESS score was not associated with age, sex, disease-related disability, retinal nerve fiber layer (RNFL), or optic neuritis (ON), but displayed an association with visual dysfunction. Conclusions: There is an increased prevalence of EDS in MS. The increased values of the ESS are not explained by other sleep disorders, suggesting separate mechanisms. Further study of the underlying mechanisms is warranted.
- 7 September 2022
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 46 (6) , 375-382
Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience
Demyelinating diseases of the central nervous system (CNS) often have neuro-ophthalmological manifestations, and retinal examination can be helpful in making the diagnosis. The latest iteration of optical coherence tomography (OCT)-based criteria for optic neuritis in multiple sclerosis has been developed in the research realm, but its application to clinical practice, and to the more uncommon demyelinating diseases requires further study. The ability to use OCT data to distinguish between various CNS demyelinating disorders could provide additional paraclinical tools to accurately diagnose patients. Furthermore, neuro-ophthalmological testing can define the extent of inflammatory damage in the CNS, independent of patient-reported history. New referrals for OCT at a tertiary multiple sclerosis and neuro-immunology referral centre (n = 167) were analysed retrospectively for the self-reporting of optic neuritis, serological test results, and diagnosis. Only approximately 30% of patients with a clinical history of unilateral optic neuritis solely had a unilateral optic neuropathy, nearly 40% of those subjects actually having evidence of bilateral optic neuropathies. Roughly 30% of patients reporting a history of bilateral optic neuritis did not have any evidence of structural disease, with 20% of these patients having a separate, intervenable diagnosis noted on macular scans. OCT is a useful adjunct diagnostic tool in the evaluation of demyelinating disease and has the ability to aid in a more accurate diagnosis for patients. Application of the international interocular difference thresholds to a clinical patient population generally reproduces the original results, emphasising their appropriateness. The analysis distinguishing the demyelinating diseases needs to be replicated in a blinded, multi-centre setting.
- 7 September 2022
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 46 (6) , 375-382
Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience
Demyelinating diseases of the central nervous system (CNS) often have neuro-ophthalmological manifestations, and retinal examination can be helpful in making the diagnosis. The latest iteration of optical coherence tomography (OCT)-based criteria for optic neuritis in multiple sclerosis has been developed in the research realm, but its application to clinical practice, and to the more uncommon demyelinating diseases requires further study. The ability to use OCT data to distinguish between various CNS demyelinating disorders could provide additional paraclinical tools to accurately diagnose patients. Furthermore, neuro-ophthalmological testing can define the extent of inflammatory damage in the CNS, independent of patient-reported history. New referrals for OCT at a tertiary multiple sclerosis and neuro-immunology referral centre (n = 167) were analysed retrospectively for the self-reporting of optic neuritis, serological test results, and diagnosis. Only approximately 30% of patients with a clinical history of unilateral optic neuritis solely had a unilateral optic neuropathy, nearly 40% of those subjects actually having evidence of bilateral optic neuropathies. Roughly 30% of patients reporting a history of bilateral optic neuritis did not have any evidence of structural disease, with 20% of these patients having a separate, intervenable diagnosis noted on macular scans. OCT is a useful adjunct diagnostic tool in the evaluation of demyelinating disease and has the ability to aid in a more accurate diagnosis for patients. Application of the international interocular difference thresholds to a clinical patient population generally reproduces the original results, emphasising their appropriateness. The analysis distinguishing the demyelinating diseases needs to be replicated in a blinded, multi-centre setting.